Dexmedetomidine Pretreatment Confers Myocardial Protection and Reduces Mechanical Ventilation Duration for Patients Undergoing Cardiac Valve Replacement under Cardiopulmonary Bypass
CONCLUSION: The study suggests that 0.50 µg/kg Dex pretreatment could reduce propofol use and the duration of mechanical ventilation, and confer myocardial protection without increased adverse events during cardiac valve replacement.PMID:38684422 | DOI:10.5761/atcs.oa.23-00210
Source: Annals of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Binglin Yuan Xiqiang Huang Junlin Wen Mengzhe Peng Source Type: research
More News: Anesthesia | Anesthesiology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Diprivan | Heart | Heart Valve Surgery | Men | Propofol | Study